Patents by Inventor Neerja Saraswat
Neerja Saraswat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11591284Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel. The compounds include phenoxy propanoic acid, phenoxy propanoate, and phenoxy butanoate compounds.Type: GrantFiled: December 14, 2017Date of Patent: February 28, 2023Assignee: NMD PHARMA A/SInventors: Lars J. S. Knutsen, Thomas Holm Pedersen, Claus Elsborg Olesen, Marc A. Labelle, Paul Brian Little, Martin E. Cooper, Neerja Saraswat, Dastagiri Dudekula, Rafiq A. Taj
-
Publication number: 20220388938Abstract: The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.Type: ApplicationFiled: June 19, 2020Publication date: December 8, 2022Applicant: NMD PHARMA A/SInventors: Lars J.S. KNUTSEN, Nicholas KELLY, Martin Brandhøj SKOV, Anders RIISAGER, Neerja SARASWAT
-
Publication number: 20220274938Abstract: The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.Type: ApplicationFiled: June 19, 2020Publication date: September 1, 2022Applicant: NMD PHARMA A/SInventors: Lars J.S. KNUTSEN, Martin BROCH-LIPS, Martin E COOPER, Marc LABELLE, Thomas Holm PEDERSEN, Dastagiri DUDEKULA, Neerja SARASWAT, Rafiq A TAJ
-
Publication number: 20190185409Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The compounds include phenoxy propanoic acid, phenoxy propanoate, and phenoxy butanoate compounds.Type: ApplicationFiled: December 14, 2017Publication date: June 20, 2019Applicant: NMD Pharma ApSInventors: Lars J.S. Knutsen, Thomas Holm Pedersen, Claus Elsborg Olesen, Marc A. Labelle, Paul Brian Little, Martin E. Cooper, Neerja Saraswat, Dastagiri Dudekula, Rafiq A. Taj
-
Publication number: 20190183812Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.Type: ApplicationFiled: December 14, 2018Publication date: June 20, 2019Applicant: NMD PHARMA A/SInventors: Lars J.S. Knutsen, Nicholas M. Kelly, Thomas Holm Pedersen, Claus Elsborg Olesen, Marc Labelle, Paul Brian Little, Martin E. Cooper, Neerja Saraswat, Dastagiri Dudekula, Rafiq A. Taj
-
Publication number: 20170369444Abstract: Compounds of the form in which Q is selected from —COOH—CH?NR12, —W, —CH2NHR13, —CH=0 and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.Type: ApplicationFiled: March 30, 2015Publication date: December 28, 2017Inventors: Marc Labelle, Rui Zhang, Cuthbert D. Martyr, Neerja Saraswat, Thomas Boesen
-
Patent number: 9802941Abstract: The present application relates to compounds being of Formula (I), (II), (III), (IV), (V), (VI), (IIIa), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), and (IIIg). Compounds of Formula (I) have the structure: wherein Q, R1, R18, R19, M, A and Y are as defined herein. The compounds of the application can modulate the activity of histone demethylases (HDMEs), and can be useful for the prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, e.g., cancer.Type: GrantFiled: August 26, 2015Date of Patent: October 31, 2017Assignee: GILEAD SCIENCES, INC.Inventors: Thomas Boesen, Marc Labelle, Ying Yang, Neerja Saraswat, Dastagiri Dudekula, Cyril John Cook, Ramkrishna Reddy Vakiti, Rui Zhang, Farman Ullah
-
Patent number: 9650339Abstract: Compounds of the form In which Q is selected from —CH?NR12, —W, —CH2NHR13, —CH?O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.Type: GrantFiled: February 26, 2014Date of Patent: May 16, 2017Assignee: GILEAD SCIENCES, INC.Inventors: Marc Labelle, Thomas Boesen, Qasim Khan, Ramkrishna Reddy Vakiti, Utpal Sharma, Ying Yang, Mukund Mehrotra, Neerja Saraswat, Farman Ullah
-
Publication number: 20160237037Abstract: Compounds of the form In which Q is selected from —CH?NR12, —W, —CH2NHR13, —CH?O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.Type: ApplicationFiled: February 26, 2014Publication date: August 18, 2016Inventors: Marc Labelle, Thomas Boesen, Qasim Khan, Ramkrishna Reddy Vakiti, Utpal Sharma, Ying Yang, Mukund Mehrotra, Neerja Saraswat, Farman Ullah
-
Publication number: 20160102096Abstract: The present application relates to compounds being of Formula (I), (II), (III), (IV), (V), (VI), (IIIa), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), and (IIIg). Compounds of Formula (I) have the structure: wherein Q, R1, R18, R19, M, A and Y are as defined herein. The compounds of the application can modulate the activity of histone demethylases (HDMEs), and can be useful for the prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, e.g., cancer.Type: ApplicationFiled: August 26, 2015Publication date: April 14, 2016Inventors: Thomas Boesen, Marc Labelle, Ying Yang, Neerja Saraswat, Dastagiri Dudekula, Cyril John Cook, Ramkrishna Reddy Vakiti, Rui Zhang, Farman Ullah
-
Patent number: 9221801Abstract: Compounds of the form In which Q is selected from —CH?NR12, —W, —CH2NHR13, —CH?O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.Type: GrantFiled: August 28, 2014Date of Patent: December 29, 2015Assignee: Epitherapeutics APSInventors: Marc Labelle, Thomas Boesen, Qasim Khan, Ramkrishna Reddy Vakiti, Utpal Sharma, Ying Yang, Mukund Mehrotra, Neerja Saraswat, Farman Ullah
-
Publication number: 20140371214Abstract: Compounds of the form In which Q is selected from —CH?NR12, —W, —CH2NHR13, —CH?O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.Type: ApplicationFiled: August 28, 2014Publication date: December 18, 2014Inventors: Marc Labelle, Thomas Boesen, Qasim Khan, Ramkrishna Reddy Vakiti, Utpal Sharma, Ying Yang, Mukund Mehrotra, Neerja Saraswat, Farman Ullah
-
Patent number: 8343944Abstract: This invention largely relates to 3,4,6-trisubstituted benzoxaborole compounds, and their use for treating bacterial infections.Type: GrantFiled: July 27, 2010Date of Patent: January 1, 2013Assignee: Anacor Pharmaceuticals, Inc.Inventors: Yi Xia, Michael Richard Kevin Alley, Yasheen Zhou, Rajeshwar Singh, Charles Ding, Kathy Cao, Jacob J. Plattner, Ligong Ou, Guofeng Jia, Neerja Saraswat, Sreekanth Ramachandran, Ding Zhou
-
Publication number: 20110136763Abstract: This invention largely relates to 3,4,6-trisubstituted benzoxaborole compounds, and their use for treating bacterial infections.Type: ApplicationFiled: July 27, 2010Publication date: June 9, 2011Applicants: Anacor Pharmaceuticals, Inc., GlaxoSmithKline LLCInventors: Yi Xia, Michael Richard Kevin Alley, Yasheen Zhou, Rajeshwar Singh, Charles Ding, Kathy Cao, Jacob J. Plattner, Ligong Ou, Guofeng Jia, Neerja Saraswat, Sreekanth Ramachandran, Ding Zhou
-
Publication number: 20100256092Abstract: This invention relates to, among other items, 6-substituted benzoxaborole compounds and their use for treating bacterial infections.Type: ApplicationFiled: May 12, 2009Publication date: October 7, 2010Applicants: Anacor Pharmaceuticals, Inc., GlaxoSmithKlineInventors: Yi Xia, Michael Richard Kevin Alley, Yasheen Zhou, Vincent S. Hernandez, Jacob J. Plattner, Charles Z. Ding, Kathy Cao, Yong-Kang Zhang, Andrew Benowitz, Tsutomu Akama, Jessica Sligar, Guofeng Jia, Ligong Ou, Neerja Saraswat, Sreekanth Ramachandran, Chris Diaper, Yanchen Zhang, Goverdhan Reddy Banda, James A. Nieman, Mehdi Keramane, Rahim Mohammed, Rajendra Subedi, Hong Liang, Rajeshwar Singh
